Australian company Immutep has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA. …
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Nobody can possibly sustain an argument this is not a price negotiation
August 15, 2025 - - Latest News -
When it comes to PBAC outcomes, it's all in the language, about pricing
August 15, 2025 - - Latest News -
Interim report calls for prevention focus to boost the nation's productivity
August 14, 2025 - - Latest News -
Just because the system involves humans, it does not make it human
August 14, 2025 - - Latest News -
Australian company Mirugen secures backing to process cell technology
August 13, 2025 - - Latest News -
AccessCR’s awards celebrate partnerships between lived experience and science
August 13, 2025 - - Latest News -
Firebrick says Nasodine COVID-19 patent accepted in Europe
August 13, 2025 - - Australian Biotech